Outlook Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 0.4935 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 120.14M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, ...